Organ preservation in locally advanced head and neck cancer of the larynx using induction chemotherapy followed by improved radiation schemes.
The present prospective study seeks to evaluate overall and disease free survival, response and organ preservation rate, and toxicity of an intensive chemotherapy regimen (CT) followed by unconventional radiotherapy (RT) in patients with locally advanced operable head and neck cancer. Between January 1998 and December 2006 (June 2005), 115 patients with locally advanced, operable head and neck cancer were evaluated. A total of 333 cycles of neoadjuvant CT (cisplatin-5FU, days 1, 14, 28) followed by hyperfractionated/accelerated radiotherapy were given to 108 patients. A total of 108 patients were evaluable and received the planned CT-RT treatment. Two months after the end of RT, 97.2% of patients had a clinical complete remission of the primary and 67.5% of the neck node site. The overall survival was 55% and cause-specific survival was 73% at 5 years. Of the 33 relapsed patients, 12 recurred only at the primary site and 10 patients had distant metastases. The overall organ preservation rate was 73.5%. The chemotherapy regimen reported an overall cardiotoxicity from 5FU in 14% of patients, with severe toxicity in 3%. The radiotherapy schedule developed 84% of Grade 3-4 mucositis in the observed patients. The accelerated CT-RT regimen is able to achieve a high rate of larynx preservation, a good tolerability, and a satisfactory cause-specific overall survival.
Franchin
Giovanni
G
Department of Radiation Therapy, Centro di Riferimento Oncologico, National Cancer Institute, Via Franco Gallini 2, 33081, Aviano, Italy. gfranchin@cro.it
Vaccher
Emanuela
E
Politi
Doriano
D
Minatel
Emilio
E
Gobitti
Carlo
C
Talamini
Renato
R
Spazzapan
Simon
S
Savignano
Maria Gabriella
MG
Trovò
Mauro G
MG
Barzan
Luigi
L
D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D003131:Combined Modality Therapy; D004334:Drug Administration Schedule; D005260:Female; D006801:Humans; D007822:Laryngeal Neoplasms / Q000188:drug therapy* / Q000473:pathology / Q000532:radiotherapy*; D008297:Male; D008875:Middle Aged; D009367:Neoplasm Staging; D016879:Salvage Therapy
Radiother Oncol. 2007 Jul;84(1):5-10
17493700
N Engl J Med. 1998 Jun 18;338(25):1798-804
9632446
J Clin Oncol. 2003 Jan 15;21(2):320-6
12525525
J Clin Oncol. 2004 May 1;22(9):1743-52
15117998
Radiother Oncol. 2003 Mar;66(3):271-6
12742266
N Engl J Med. 1991 Jun 13;324(24):1685-90
2034244
Laryngoscope. 1988 Nov;98(11):1205-11
3054373
J Clin Oncol. 2004 Sep 1;22(17):3540-8
15337803
J Clin Oncol. 2006 Mar 1;24(7):1064-71
16505425
J Clin Oncol. 2002 Mar 1;20(5):1405-10
11870186
Cancer. 1990 Apr 15;65(8):1685-91
2317751
Am J Clin Oncol. 2005 Aug;28(4):371-8
16062079
Int J Radiat Oncol Biol Phys. 1992;23(4):705-13
1618662
J Clin Oncol. 2006 Feb 1;24(4):593-8
16380415
J Natl Cancer Inst. 1999 Dec 15;91(24):2081-6
10601378
N Engl J Med. 2007 Oct 25;357(17):1705-15
17960013
J Clin Oncol. 2002 Oct 1;20(19):3964-71
12351593
Oral Oncol. 2005 May;41(5):526-33
15878759
N Engl J Med. 2003 Nov 27;349(22):2091-8
14645636
J Clin Oncol. 2005 May 1;23(13):3008-15
15860857
J Clin Oncol. 2004 Jan 1;22(1):69-76
14657228
J Natl Cancer Inst. 1994 Feb 16;86(4):265-72
8158680
J Clin Oncol. 2004 Aug 1;22(15):3061-9
15284256
J Natl Cancer Inst. 1996 Jul 3;88(13):890-9
8656441
Int J Radiat Oncol Biol Phys. 2000 Aug 1;48(1):7-16
10924966
J Natl Cancer Inst. 1996 May 1;88(9):583-9
8609658
Cancer J. 2002 Jul-Aug;8(4):311-21
12184409
Lancet. 2000 Mar 18;355(9208):949-55
10768432
N Engl J Med. 2006 Feb 9;354(6):567-78
16467544